Payment overview · 2025
General Payments
1 reported records · 1 companies
Healthcare provider profile · identity verified
Allopathic & Osteopathic Physicians|Family Medicine · MORENO VALLEY, CA · NPI 1871566778
Verified facts
CMS Open Payments records show Benito B Perez, M.D. received $50.42 in general payments during 2025 across 1 reported records.
Amgen Inc. accounted for 100.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 1 associated product.
These records do not establish that a payment influenced prescribing or medical care.
Payment overview · 2025
1 reported records · 1 companies
Separate record types
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $50.42 | 100.0% | 1 | 2025 |
What were the payments for?
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $50.42 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $50.42 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
No publishable same-company prescribing overlap was found in the loaded Part D year. This does not mean the doctor never prescribed a drug reported elsewhere by a paying company.
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 723 | 249 |
| Meloxicam | Meloxicam | 283 | 91 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 252 | 91 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 233 | 82 |
| Amlodipine Besylate | Amlodipine Besylate | 223 | 80 |
| Lisinopril | Lisinopril | 215 | 74 |
| Losartan Potassium | Losartan Potassium | 201 | 69 |
| Levothyroxine Sodium | Levothyroxine Sodium | 191 | 62 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 186 | 41 |
| Metformin Hcl Er | Metformin Hcl | 176 | 56 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 155 | 52 |
| Metformin Hcl | Metformin Hcl | 155 | 56 |
| Omeprazole | Omeprazole | 150 | 56 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 132 | 50 |
| Gabapentin | Gabapentin | 105 | 27 |
| Alendronate Sodium | Alendronate Sodium | 104 | 35 |
| Pradaxa | Dabigatran Etexilate Mesylate | 104 | 29 |
| Ozempic | Semaglutide | 103 | 16 |
| Pantoprazole Sodium | Pantoprazole Sodium | 96 | 35 |
| Jardiance | Empagliflozin | 94 | 28 |
| Potassium Chloride | Potassium Chloride | 94 | 33 |
| Hydrochlorothiazide | Hydrochlorothiazide | 93 | 37 |
| Simvastatin | Simvastatin | 93 | 34 |
| Ibuprofen | Ibuprofen | 92 | 30 |
| Glipizide | Glipizide | 90 | 32 |
| Terazosin Hcl | Terazosin Hcl | 88 | 30 |
| Metoprolol Tartrate | Metoprolol Tartrate | 81 | 31 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 80 | 33 |
| Tamsulosin Hcl | Tamsulosin Hcl | 79 | 29 |
| Mirtazapine | Mirtazapine | 77 | 31 |
| Atenolol | Atenolol | 74 | 24 |
| Duloxetine Hcl | Duloxetine Hcl | 67 | 26 |
| Trazodone Hcl | Trazodone Hcl | 67 | 29 |
| Sertraline Hcl | Sertraline Hcl | 65 | 22 |
| Glipizide Er | Glipizide | 63 | 23 |
| Humulin N | Insulin Nph Human Isophane | 62 | 18 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 58 | 24 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 54 | suppressed |
| Furosemide | Furosemide | 52 | 20 |
| Allopurinol | Allopurinol | 45 | 16 |
| Hydrocortisone | Hydrocortisone | 45 | 26 |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 43 | 12 |
| Escitalopram Oxalate | Escitalopram Oxalate | 41 | 13 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 41 | 17 |
| Carvedilol | Carvedilol | 40 | 13 |
| Ciclopirox | Ciclopirox | 40 | 21 |
| Ondansetron Odt | Ondansetron | 38 | 13 |
| Veo Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 36 | 13 |
| Quetiapine Fumarate | Quetiapine Fumarate | 33 | suppressed |
| Colchicine | Colchicine | 32 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 32 | 13 |
| Tramadol Hcl | Tramadol Hcl | 32 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 31 | suppressed |
| Ezetimibe | Ezetimibe | 30 | 12 |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 30 | 13 |
| Adacel Tdap | Diph,pertuss(Acell),tet Vac/Pf | 28 | 28 |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 28 | suppressed |
| Acyclovir | Acyclovir | 27 | suppressed |
| Alvesco | Ciclesonide | 27 | 11 |
| Ondansetron Hcl | Ondansetron Hcl | 26 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 26 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 25 | suppressed |
| Alprazolam | Alprazolam | 25 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 24 | 21 |
| Finasteride | Finasteride | 24 | suppressed |
| Latanoprost | Latanoprost | 24 | suppressed |
| Lorazepam | Lorazepam | 24 | suppressed |
| Lovastatin | Lovastatin | 24 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 24 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 23 | suppressed |
| Eliquis | Apixaban | 22 | suppressed |
| Nystatin | Nystatin | 22 | suppressed |
| Prednisone | Prednisone | 22 | 20 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 22 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 21 | suppressed |
| Mupirocin | Mupirocin | 21 | suppressed |
| Nitroglycerin | Nitroglycerin | 21 | suppressed |
| Veo Insulin Syringe | Syringe And Needle,insulin,1ml | 21 | suppressed |
| Famotidine | Famotidine | 20 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 20 | suppressed |
| Fluorouracil | Fluorouracil | 19 | 15 |
| Spironolactone | Spironolactone | 19 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 19 | suppressed |
| Baclofen | Baclofen | 18 | suppressed |
| Calcipotriene | Calcipotriene | 18 | 13 |
| Clopidogrel | Clopidogrel Bisulfate | 18 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 18 | suppressed |
| Tadalafil | Tadalafil | 18 | suppressed |
| Estradiol | Estradiol | 17 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 17 | suppressed |
| Pregabalin | Pregabalin | 17 | suppressed |
| Topiramate | Topiramate | 17 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 17 | suppressed |
| Veo Insulin Syringe | Syrge-Ndl,ins 0.3 Ml Half Mark | 17 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 16 | 16 |
| Citalopram Hbr | Citalopram Hydrobromide | 16 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 16 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 16 | suppressed |
| Fenofibrate | Fenofibrate | 15 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 15 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 15 | suppressed |
| Xarelto | Rivaroxaban | 15 | suppressed |
| Amoxicillin | Amoxicillin | 14 | suppressed |
| Cephalexin | Cephalexin | 14 | 13 |
| Fluticasone Propionate | Fluticasone Propionate | 14 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 14 | suppressed |
| Valsartan | Valsartan | 14 | suppressed |
| Victoza 2-Pak | Liraglutide | 14 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 13 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 13 | suppressed |
| Ketoconazole | Ketoconazole | 13 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 13 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 12 | suppressed |
| Methadone Hcl | Methadone Hcl | 12 | suppressed |
| Methocarbamol | Methocarbamol | 12 | suppressed |
| Naproxen | Naproxen | 12 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 12 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 12 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 11 | suppressed |
| Clonazepam | Clonazepam | 11 | suppressed |
| Humulin N Kwikpen | Insulin Nph Human Isophane | 11 | suppressed |
| Lidocaine | Lidocaine | 11 | suppressed |
| Nabumetone | Nabumetone | 11 | suppressed |
| Polymyxin B Sul-Trimethoprim | Polymyxin B Sulf/Trimethoprim | 11 | suppressed |
Timeline
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $50.42 · 1 records | Amgen Inc. | REPATHA | — | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error